Home › Funds › VALLEY FORGE INVESTMENT CONSULTANTS INC ADV › SPRY

VALLEY FORGE INVESTMENT CONSULTANTS INC ADV position in SPRY

ARS PHARMACEUTICALS INC · Health Care

VALLEY FORGE INVESTMENT CONSULTANTS INC ADV reported holding 83,225 shares of SPRY (ARS PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$667K, representing 0.17% of its reported portfolio and ranking #43 among its reported holdings. VALLEY FORGE INVESTMENT CONSULTANTS INC ADV has disclosed SPRY holdings in 8 of the last 8 reported quarters, going back to Q3 2024.

Latest position (Q2 2026)83.22K sh
Reported value held$666.63K
Portfolio Weight0.17%
First reportedQ3 2024
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How VALLEY FORGE INVESTMENT CONSULTANTS INC ADV's SPRY position evolved

VALLEY FORGE INVESTMENT CONSULTANTS INC ADV first disclosed a stake in SPRY in Q3 2024 at 83,225 shares (US$1.2M). The position peaked in Q2 2025 at 83,225 shares, worth US$1.5M. Across 8 filings, VALLEY FORGE INVESTMENT CONSULTANTS INC ADV held the position steady without any share-count change. The most recent filing (Q2 2026) shows 83,225 shares valued at US$667K.

Quarter by quarter

QuarterSharesValueChange
Q3 2024 83.22K $1.21M New
Q4 2024 83.22K $878.02K Hold
Q1 2025 83.22K $1.05M Hold
Q2 2025 83.22K $1.45M Hold
Q3 2025 83.22K $836.41K Hold
Q4 2025 83.22K $969.57K Hold
Q1 2026 83.22K $668.30K Hold
Q2 2026 83.22K $666.63K Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About SPRY and 13F data

SPRY (ARS PHARMACEUTICALS INC) is a Health Care company. 25 other funds we track also report a position in SPRY — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$87.0M), Rubric Capital Management LP (US$68.4M), ORBIMED ADVISORS LLC (US$66.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding SPRY

All SPRY fund holders →

FAQ

How long has VALLEY FORGE INVESTMENT CONSULTANTS INC ADV held SPRY?

VALLEY FORGE INVESTMENT CONSULTANTS INC ADV has disclosed SPRY holdings in 8 of the last 8 reported quarters, going back to Q3 2024.

What is VALLEY FORGE INVESTMENT CONSULTANTS INC ADV's current position in SPRY?

As of Q2 2026, VALLEY FORGE INVESTMENT CONSULTANTS INC ADV holds 83.22K shares of SPRY (ARS PHARMACEUTICALS INC), valued at $666.63K, representing 0.17% of its reported portfolio and ranking #43.

Has VALLEY FORGE INVESTMENT CONSULTANTS INC ADV been buying or selling SPRY?

In the latest 13F filing (Q2 2026), VALLEY FORGE INVESTMENT CONSULTANTS INC ADV held unchanged its position in SPRY. The position peaked in Q2 2025 at 83.22K shares.

Which other funds hold SPRY?

Other major institutional holders of SPRY include RA CAPITAL MANAGEMENT, L.P., Rubric Capital Management LP, ORBIMED ADVISORS LLC, among 25 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.